Table 2.
Resume of the biological approaches used for treatment of GBS in human studies.
| Drugs | Biological Approach | Type of Study | Subjects | Efficient /Non-efficient | Year and Author |
|---|---|---|---|---|---|
| Anti-T cell monoclonal Ab (OK3) | T cell modulation | Original article | 3 adult GBS patients | Non-efficient | 1991/Feasby [54] |
| IFNβ | Cytokine modulation | Case report | 1 adult GBS patient | Efficient | 1998/Creange [77] |
| IFNβ | Cytokine modulation | Original article | 26 GBS patients & 6 healthy controls |
Efficient | 2001/Creange [79] |
| IFNβ + IVIg | Cytokine modulation | Case report | 1 adult GBS patient | Efficient | 2001/ Schaller [80] |
| IFNβ + IVIg | Cytokine modulation | Randomized controlled clinical trial | 13 GBS cases (IFNβ+IVIg) & 6 GBS controls (Placebo+IVIg) |
Non-efficient | 2003/Pritchard [81] |
| Rituximab | B cell modulation | Case report | 1 adult GBS patient | Efficient | 2008/Ostronoff [65] |
| Eculizumab | Complement modulation | Case report | 1 pediatric GBS patient | Efficient | 2014/Ram [42] |
| Alemtuzumab | T and B cell modulation | Case report | 1 adult GBS patient | Efficient | 2014/Tzachanis [74] |
| Eculizumab | Complement modulation | Clinical trial | Unknown | Unfinished | 2014 start/Glasgow [43] |
| Eculizumab | Complement modulation | Clinical trial | Unknown | Unfinished | 2015 start/Kuwabara [44] |